Low-toxicity treatment for colorectal cancer in elderly people
Mené sur 280 patients d'âge supérieur à 70 ans et atteints d'un cancer colorectal métastatique, cet essai multicentrique international de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout de bevacizumab à la capécitabine
Since the introduction of systemic fluoropyrimidine with folinic acid in the early 1990s, the outlook of patients with metastatic colorectal cancer has greatly improved. Although fluoropyrimidine with folinic acid alone resulted in only a median overall survival of about 12 months in early phase 3 studies, median survival longer than 22 months has been routinely achieved with irinotecan-based or oxaliplatin-based chemotherapies, effective second-line and third-line treatments, and molecular ther ...
The Lancet Oncology , commentaire, 2012